ovarian cancer Archives -

Shares in VBL Therapeutics have lost around 78% of their value in pre-market trading after the company reported

VBL craters as ovarian cancer gene therapy fails phase 3 test

https://pharmaphorum.com/news/vbl-craters-as-ovarian-cancer-gene-therapy-fails-phase-3-test/

ASCO22: New data backs BMS’ investment in Eisai’s first cancer ADC

Phil Taylor antibody-drug conjugate, Bristol-Myers Squibb, Eisai, immunogen, Oncology, ovarian cancer 0 Comment

Eisai’s first-ever attempt at developing an antibody-drug conjugate for cancer was rewarded with a $3.1 billion licensing deal

ASCO22: New data backs BMS’ investment in Eisai’s first cancer ADC

https://pharmaphorum.com/news/asco22-new-data-backs-bms-investment-in-eisais-first-cancer-adc/

News/ News/ Oncology

GSK’s ZEJULA gets green light for NHS use

Eloise McLennan GSK, NHS, NICE, ovarian cancer, regulatory approval 0 Comment

The UK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some

GSK’s ZEJULA gets green light for NHS use

https://pharmaphorum.com/news/gsk-zejula-niraparib-gets-green-light-for-nhs-use/

News/ News/ Oncology

UK startup Leucid raises £11.5m for solid tumour CAR-T therapies

Phil Taylor CAR-T therapies, financing, immuno-oncology, Leucid Bio, Oncology, ovarian cancer 0 Comment

CAR-T therapies have revolutionised the treatment of some blood cancers, but so far haven’t been able to repeat

UK startup Leucid raises £11.5m for solid tumour CAR-T therapies

https://pharmaphorum.com/news/uk-startup-leucid-raises-11-5m-for-solid-tumour-car-t-therapies/

Digital/ Views & Analysis/ Views and analysis

Shaping the future of ovarian cancer diagnosis with femtech

Catherine Longworth AI, data science, digital health, femtech, GinaLife, ovarian cancer 0 Comment

Israeli femtech start-up GinaLife is developing a platform of biomarker strategies supported by artificial intelligence and data science

Shaping the future of ovarian cancer diagnosis with femtech

https://pharmaphorum.com/digital/ginalife-ovarian-cancer-diagnosis-femtech/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

Market Access/ News/ News

NICE backs ovarian cancer and multiple myeloma combination drugs

Richard Staines market access, multiple myeloma, NICE, ovarian cancer 0 Comment

NICE has recommended funding for two cancer drug combinations for ovarian cancer and multiple myeloma. In final draft

NICE backs ovarian cancer and multiple myeloma combination drugs

https://pharmaphorum.com/news/nice-backs-ovarian-cancer-and-multiple-myeloma-combination-drugs/

News/ News/ Oncology

EU regulators back uses for AZ’s Lynparza in prostate and ovarian cancer

Richard Staines AstraZeneca, cancer, ovarian cancer, Prostate cancer 0 Comment

AstraZeneca may have had a rough ride following a safety scare with its COVID-19 vaccine, but the company’s

EU regulators back uses for AZ’s Lynparza in prostate and ovarian cancer

https://pharmaphorum.com/news/az-grabs-twin-eu-approval-for-lynparza-in-prostate-and-ovarian-cancer-uses/

News/ News/ Oncology

Roche’s Tecentriq cocktail fails in newly-diagnosed ovarian cancer

Richard Staines cancer, immunotherapy, ovarian cancer, Roche, Tecentriq 0 Comment

A cocktail of drugs including Roche’s Tecentriq has failed to improve progression-free survival in ovarian cancer patients, before or after surgery. Roche had

Roche’s Tecentriq cocktail fails in newly-diagnosed ovarian cancer

https://pharmaphorum.com/news/roches-tecentriq-cocktail-fails-in-newly-diagnosed-ovarian-cancer/

News/ News/ Oncology

AZ/Merck & Co’s Lynparza sets ‘new standards’ in ovarian cancer

Richard Staines asco, AstraZeneca, Merck & Co, Oncology, ovarian cancer 0 Comment

AstraZeneca and Merck & Co’s Lynparza should be the standard therapy for a certain group of ovarian cancer patients according to US

AZ/Merck & Co’s Lynparza sets ‘new standards’ in ovarian cancer

https://pharmaphorum.com/news/azs-lynparza-sets-new-standards-in-ovarian-cancer-say-experts/

Trending

ovarian cancer

Login